APGE Quote, Financials, Valuation and Earnings

Aveanna Healthcare Holdings, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of 2.26%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Aveanna Healthcare Holdings, Inc.'s return on equity of --.

Apogee Therapeutics, Inc. has a consensus price target of $96.55, signalling upside risk potential of 25.79%. On the other hand Aveanna Healthcare Holdings, Inc. has an analysts' consensus of $10.55 which suggests that it could grow by 13.32%. Given that Apogee Therapeutics, Inc. has higher upside potential than Aveanna Healthcare Holdings, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Aveanna Healthcare Holdings, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Aveanna Healthcare Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aveanna Healthcare Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Aveanna Healthcare Holdings, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Aveanna Healthcare Holdings, Inc. quarterly revenues of $621.9M. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Aveanna Healthcare Holdings, Inc.'s net income of $14.1M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Aveanna Healthcare Holdings, Inc.'s PE ratio is 25.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 0.86x for Aveanna Healthcare Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of -301.29%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Nektar Therapeutics's return on equity of -327.67%.

Apogee Therapeutics, Inc. has a consensus price target of $96.55, signalling upside risk potential of 25.79%. On the other hand Nektar Therapeutics has an analysts' consensus of $107.29 which suggests that it could grow by 88.55%. Given that Nektar Therapeutics has higher upside potential than Apogee Therapeutics, Inc., analysts believe Nektar Therapeutics is more attractive than Apogee Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.268, suggesting its more volatile than the S&P 500 by 26.844%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 58.67x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of 38.89%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Apogee Therapeutics, Inc. has a consensus price target of $96.55, signalling upside risk potential of 25.79%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $781.13 which suggests that it could grow by 8.74%. Given that Apogee Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.369, suggesting its less volatile than the S&P 500 by 63.095%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.49% to investors and pays a quarterly dividend of $0.88 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 17.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 5.56x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.